A Study of ELX-02 in Patients With Alport Syndrome

Clinical trial NCT05448755 · COMPLETED

Trial details

NCT number: NCT05448755
Sponsor: Eloxx Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Alport Syndrome

Start date: 2022-11-28
Primary completion: 2023-09-11
Enrollment: 3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.